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Abstract Mature circulating endothelial cell (CEC) as
well as endothelial progenitor populations may reflect the
activity of anti-angiogenic agents on tumor neovasculature
or even constitute a target for anti-angiogenic therapy. We
investigated the behavior of CECs in parallel with hema-
topoietic progenitor cells (HPCs) in the blood of renal cell
cancer patients during sunitinib treatment. We analyzed the
kinetics of a specific population of small VEGFR2-
expressing CECs (CD45neg/CD34bright), HPCs (CD45dim/
CD34bright), and monocytes in the blood of 24 renal cell
cancer (RCC) patients receiving 50 mg/day of the multi-
targeted VEGF inhibitor sunitinib, on a 4-week-on/2-week-
off schedule. Blood was taken before treatment (C1D1), on
C1D14, C1D28, and on C2D1 before the start of cycle 2.
Also plasma VEGF and erythropoietin (EPO) were deter-
mined. Remarkably, while CD34bright HPCs and monocytes
decreased during treatment, CD34bright CECs increased
from 69 cells/ml (C1D1) to 180 cells/ml (C1D14;
P = 0.001) and remained high on C1D28. All cell popu-
lations recovered to near pre-treatment levels on C2D1.
Plasma VEGF and EPO levels were increased on C1D14
and partly normalized to pre-treatment levels on C2D1. In
conclusion, opposite kinetics of two circulating CD34bright
cell populations, HPCs and small CECs, were observed in
sunitinib-treated RCC patients. The increase in CECs is
likely caused by sunitinib targeting of immature tumor
vessels.
Keywords Circulating endothelial (progenitor) cells 
Renal cell cancer patients  Sunitinib  VEGF 
Erythropoietin
Introduction
Anti-angiogenic compounds have shown efficacy in the
clinic during recent years. In particular, the anti-vascular
endothelial growth factor (VEGF) antibody bevacizumab
[1] and the receptor tyrosine kinase inhibitors (TKIs) of the
VEGF receptor family [2], sunitinib [3, 4] and sorafenib
[5], have proven activity in a number of tumor types [6].
Sunitinib is an oral TKI of the VEGF receptors, platelet-
derived growth factor (PDGF) receptors, Flt-3 and c-Kit,
and has been approved for treatment of advanced renal cell
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cancer (RCC) and imatinib-resistant gastrointestinal stro-
mal tumors (GISTs). In a phase III trial in RCC patients,
sunitinib has proven to be effective, albeit that a subset of
RCC patients did not benefit from it [4]. Therefore, there is
still a need for better understanding which conditions,
factors, and cells facilitate or limit the beneficial effects of
sunitinib on tumors.
In addition to immunohistochemical staining of tumor
biopsies and imaging techniques that quantify tumor
growth and perfusion [7], measurement of plasma circu-
lating proteins, such as VEGF [8] or soluble VEGFRs [9],
may reflect responsiveness to treatment. However, VEGF
or sVEGFR2 plasma levels have not been shown to be
predictive of response to sunitinib in GIST patients [10].
Alternatively, changes in the levels of circulating cells,
such as newly recruited progenitor cells and monocytes or
detached endothelial cells may be induced by anti-angio-
genic treatment [7, 11].
Circulating endothelial progenitor (CEPs) cells have
been suggested as potential pharmacodynamic or predic-
tive biomarker in tumor patients [11]. CEPs were first
described by Asahara et al. [12], who introduced the con-
cept of circulating, bone marrow-derived endothelial
progenitor cells, contributing to adult vasculogenesis.
Later, Lyden et al. [13] have demonstrated that both
VEGFR2pos-circulating endothelial cells as well as
VEGFR1pos-myeloid, monocytic cells contributed to tumor
vascularization. Recently, the source of highly proliferative
endothelial outgrowth cells (EOCs) has been identified in
CD34pos/CD45neg/CD133neg circulating cell populations
[14, 15]. Besides CEPs, circulating endothelial cells
(CECs) as thought to be shed from mature blood vessels
may reflect the efficacy of anti-vascular treatment, as
suggested in a number of studies [10, 16–18]. At present,
no studies have reported on changes in frequencies of
CECs or CEPs in combination with hematopoietic pro-
genitor cells (HPCs) during sunitinib treatment of RCC
patients.
Previously, we have identified a rare population of small
CD45neg/CD34bright/CD133neg/VEGFR2pos cells in the
peripheral blood (PB) of healthy volunteers, with increased
numbers in cancer patients [19]. On the basis of endothelial
marker expression these cells were indicated as ‘‘small-size
EC-like cells’’ or CECs [20], because they are relatively
small (\10 lm) when compared with mature CECs
[21–23]. Also, their marker profile is the same as that of the
source of highly proliferative late outgrowth endothelial
cells present in umbilical cord blood or PB [15] and is
clearly distinct from CD45dim/CD34bright/CD133? hema-
topoietic progenitors. Here, we demonstrate that these
CECs increase during sunitinib treatment of RCC patients
in parallel to plasma VEGF and erythropoietin (EPO)
levels, while HPCs and monocytes show the opposite
changes, i.e., a decrease. In addition, a preliminary evalu-
ation of the relation of CECs with clinical response is
discussed.
Patients and methods
Patients and study design
From January 2006 to March 2007, 24 patients treated with
sunitinib for advanced RCC in an expanded access pro-
gram were included.
Sunitinib was administered orally, as monotherapy, at
the currently recommended dose of 50 mg daily in cycles
of 6 weeks, consisting of 4 weeks on treatment followed
by 2 weeks of rest (4/2 schedule). Before study entry, each
participant signed an institutional review board-approved
protocol-specific informed consent in accordance with
national and institutional guidelines, which strictly adhere
to the principles of the Declaration of Helsinki and its
subsequent amendments. During cycle 1, PB was taken on
four occasions: C1D1 before receiving the first dose of
sunitinib, C1D14, C1D28, and C2D1 (=C1D42) before
administration of sunitinib of cycle 2. Computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) was
performed before treatment and after every two to three
cycles to assess clinical response according to response
evaluation criteria in solid tumors (RECIST) [24]. RECIST
is based on the sum of the largest diameters of appointed
target tumor lesions at baseline and compared with the sum
calculated in follow-up scans. Progression was defined
based on 20% increase in the sum of the target lesions or
clear clinical evidence of progressive disease (PD), and a
20% decrease in the sum of the target lesions was con-
sidered as partial response (PR). Responses not fitting these
criteria were considered as stable disease (SD). Tumor
response, PFS, and overall survival (OS) were used as
parameters of treatment outcome. The PFS was the time
between the first day of sunitinib and the date of PD on CT
or MRI or clear clinical evidence of PD. OS was the time
between the first day of treatment and the date of death or
the date on which patients were last known to be alive.
Data collection was closed on January 1st, 2008.
HPCs, CECs, and plasma monitoring
At the time of blood sampling, the first 2 ml of blood was
discarded and blood for flow cytometric enumerations was
processed within 2–4 h. At each time-point, 7 ml of EDTA
blood and 7 ml of citrate blood in a CPT tube (Becton
Dickinson) were collected for measurement of circulating
cell populations. One milliliter of full blood was used for
the measurement of CECs and HPCs, based on CD45 and
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CD34 marker expression and expressed as number per
milliliter, as published in detail [19]. Analysis of the sub-
sets of cells was performed with the antibodies CD45-
FITC, CD34-APC, and IgG isotypes as has been described
in detail [19]. For additional measurements of cell popu-
lations in patients, VEGFR2-APC and -PE antibodies were
used. The viability marker 7-AAD was used to gate viable
cells and annexin-V staining was used to determine early
stages of apoptosis. To assure the gating of nucleated small
CD34bright cells only, in a number of patients, we added
extra analysis tubes using the dye styril-751 (LDS-751).
Furthermore, we added tubes with 7-AAD plus 0.1%
saponin to permeabilize the cells and allow access of the
dye to nuclei of viable cells as described before [19, 25].
Flow cytometry was performed on a FACSCalibur (BD
Biosciences) and data were analyzed using CellQuest Pro
software. Subfractions of white blood cells (WBC) were
calculated as number per milliliter of blood by using
standard total WBC count on Sysmex [19]. The remaining
EDTA blood was used for the preparation of plasma and
stored at -80C. Plasma VEGF levels and EPO were
measured in duplicate with enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, Minneapolis). Albumin
was determined using conventional methods in the
department of clinical chemistry.
Human umbilical cord blood was obtained from full-
term deliveries and was processed for flow cytometry,
according to the patients PB samples and used as a refer-
ence to identify the CD45neg/CD34bright/CD133neg CEC
population [15].
Statistics
Frequencies of circulating cell populations (numbers/ml),
plasma levels of VEGF (pg/ml), and EPO (mIU/ml) were
enumerated and expressed as median (range). Wilcoxon
Signed Ranks test (SPSS for Windows 14.0, SPSS, Inc.,
Chicago, IL) was used to compare the biomarkers at
pre-treatment and during treatment on C1D14, C1D28,
and C2D1. Clinical benefit (CB) was defined as SD
plus PR. PFS and OS were calculated with the Kaplan–
Meier method and tested with the log rank test. Values
of P B 0.05 (two-sided) were considered statistically
significant.
Results
Patient characteristics and response to treatment
Twenty-four RCC patients treated with sunitinib were
enrolled in the study. One patient died on C1D14, due to
early progression and was excluded from the analysis. The
remaining patients (17 males and 6 females) had a median
age of 63 years (range 40–84) at the start of treatment. For
further patients characteristics, see Tables 1 and 2.
Two out of twenty-three patients could not be evaluated
for treatment response because of early discontinuation due
to sunitinib-related side-effects. Of the 21 evaluable
Table 1 Patient characteristics and best response to sunitinib
treatment
Characteristic No. %
Total 23 100
Sex
Male 17 74
Female 6 26
Median age, years (range) 63 (40–84)
Histology
Clear cell 19 83
Papillary 3 13
Other 1 4
Prior treatment
Prior nephrectomy 17 74
Prior cytokine-based therapy 15 65
Site of metastatic disease
Lung 20 87
Liver 9 39
Bone 4 17
No. of disease sites
1 3 13
2 5 22
C3 15 65
MSKCC risk groups [53]
Favorable risk 3 13
Intermediate risk 15 65
Poor risk 5 22
Best response to sunitinib treatmenta
Partial response 4 17 (19)
Stable disease 11 48 (52)
Progressive disease 6 26 (29)
No evaluationb 2 7 (–)
Progression-free survivalc 8.0 (1.1–19.3) –
Survivald 12.7 (1.4–23.2) –
MSKCC, Memorial Sloan-Kettering Cancer Center
a CT or MRI was performed before treatment and after every two to
three cycles to assess clinical response according to response evalu-
ation criteria in solid tumors (RECIST) [24]
b Two out of 23 patients could not be evaluated for treatment
response because of early discontinuation due to sunitinib related
side-effects
c The PFS was the time between the first day of sunitinib and the date
of progressive disease (PD) on CT or MRI or clear clinical evidence
of PD
d Survival was the time between the first day of treatment and the
date of death or the date on which patients were last known to be alive
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patients, 4 patients (19%) achieved a PR as best response,
11 patients (52%) had SD, and 6 patients (29%) had PD.
The median PFS of these 23 patients was 8.0 months
(range 1.1–19.3) and the median OS was 12.7 months
(range 1.4–23.2).
Blood cell counts during the first cycle of sunitinib
The median WBC count of the patients showed a decrease
from 7.9 9 106 to 6.9 9 106 cells/ml on C1D14 (n = 23;
P = 0.002) and a further decrease on C1D28 (from median
pre-treatment 7.9 9 106 to 4.4 9 106 cells/ml, n = 15;
P = 0.001), which partly reverted after 2 weeks of rest
(from median pre-treatment 7.7 9 106 to 4.8 9 106,
n = 15; P = 0.001). A similar pattern was seen for
thrombocytes, neutrophils, and monocytes. The reduction
of circulating monocytes and their partial recovery pro-
ceeded faster than the total WBC change, whereas the
neutrophil decrease showed a more delayed effect. Eryth-
rocytes and hemoglobin showed the reverse, i.e., a
significant increase after 14 and 28 days, while the number
of lymphocytes and basophils did not change during sun-
itinib treatment (Fig. 1).
Marker profile of two CD34bright populations: CECs
and HPCs
Two populations of CD34bright circulating cells were
evaluated, CECs and HPCs. The definitions of CECs and
HPCs, according to CD45 and CD34 expression are visu-
alized for a representative RCC patient (Fig. 2a) and for
comparison from cord blood (Fig. 2b). CECs are CD45neg
and CD133neg; HPCs are CD45dim and are largely
CD133pos (Fig. 2a, b). Moreover, CECs have a slightly
higher CD34 brightness than the majority of HPCs [19].
CECs are small in size being comparable with HPCs. CECs
are viable cells, because they all exclude 7-AAD. We also
checked in separate analysis tubes that both the CD34bright
CD45neg and CD34bright CD45dim population had a similar
positive 7-AAD/saponin staining as well as LDS-751
staining, confirming that both populations are nucleated
cells. Other markers for which CECs are positive are
Table 2 Patients characteristics and best response to sunitinib
Patient no. Age (years) Sex RCC type Prior treatment Responsea PFS (months) Survival (months)
1 68 F Clear cell Second-line PR 18.4 23.2
2 48 M Clear cell Second-line PD 3.0 8.2
3 40 M Papillary ca Second-line SD 10.1 11.0
4 76 M Clear cell Second-line SD 7.0 12.3
5 57 M Clear cell Second-line SD 10.6 22.2
6 62 F Clear cell Second-line PR 5.8 20.7
7 66 M Papillary ca Second-line PD 1.2 1.4
8 60 M Clear cell Second-line PR 19.4 19.3
9 81 M Clear cell Second-line SD 11.0 11.2
10 45 M Papillary ca Second-line PD 2.6 4.6
11 70 M Clear cell First-line SD 8.4 9.1
12 59 M Clear cell First-line SD 9.3 15.5
13 59 M Clear cell First-line PD 2.6 10.9
14 73 F Clear cell First-line SD 3.6 4.6
15 74 M Clear cell First-line SD 2.0 14.9
16 59 M Clear cell Second-line PR 8.9 12.7
17 57 F Clear cell First-line – – 9.7
18 69 F Clear cell First-line SD 16.5 16.5
19 84 F Clear cell Second-line – – 16.6
20 60 M Clear cell Second-line SD 8.0 15.3
21 57 M Clear cell Second-line PD 2.3 13.8
22 48 M Chromophobe ca First-line PD 1.1 2.0
23 64 M Clear cell Second-line SD 5.1 9.0
RCC, renal cell cancer; F, female; M, male; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival
a According to response evaluation criteria in solid tumors
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CD31, CD105, CD146, and VEGFR2, as previously
reported [19]. To confirm the VEGFR2 expression on
CECs, we have measured VEGFR2 in parallel, in addi-
tional cancer patients. VEGFR2 positivity in CECs was
high (median 65%), in contrast to the CD45dim/CD34bright
HPCs (\1%). In addition, the EPO receptor was evaluated
on CECs of five sunitinib-treated patients and was found
present in 83.3% of the CECs (median range 66.7–93.3%).
Plasma membrane VE-cadherin was undetectable in CECs
in five treated patients (data not shown).
Kinetics of CECs and HPCs during the first cycle
of sunitinib
A distinct difference in the kinetics of CECs (CD45neg/
CD34bright/7-AADneg) and HPCs (CD45dim/CD34bright/
Fig. 1 Blood cell count and
hemoglobin during treatment
with sunitinib. Median (range)
values are shown. Timepoints of
measurement: C1D1, cycle
1 day 1 (n = 23); C1D14, cycle
1 day 14 (n = 23); C1D28,
cycle 1 day 28 (n = 15); C2D1,
cycle 2 day 1 before start of the
second cycle (n = 15).
Wilcoxon Signed rank test,
* P \ 0.01, ** P \ 0.05
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7-AADneg) was observed during the first cycle of sunitinib
(Fig. 3a). The median number of viable CECs before
treatment (C1D1) was 69 cells/ml (range 8–472), much
lower than the number of HPCs (1,350 cells/ml, range
305–5,351). The median of CECs increased from 69 on
C1D1 to 180 cells/ml on C1D14 (n = 23; P = 0.001) and
from pre-treatment 76 to 229 cells/ml (n = 14; P = 0.013)
on C1D28, while the HPCs displayed an opposite kinetic
pattern and decreased from 1,350 to 372 cells/ml on C1D14
(n = 23; P \ 0.001) and from pre-treatment 1,567 to 409
cells/ml on C1D28 (n = 14; P = 0.001). Both cell popu-
lations returned to values close to the pre-treatment levels
after the 2-week period of rest (C2D1; Fig. 3a). In a group
of non-small cell lung cancer patients not treated with a
VEGFR inhibitor, but treated with the EGF receptor
inhibitor erlotinib, the CECs did not change significantly
over a 3-week period (data not shown).
When the kinetic changes in circulating cells were
expressed as percentage of pre-treatment values within
individual patients, 102% increase in CECs numbers was
observed after 2 weeks of treatment, whereas the HPCs
showed a 65% decrease (Fig. 3b). A similar change was
found on C1D28 (n = 14).
Plasma VEGF and EPO levels during the first cycle
of sunitinib
Plasma levels of VEGF before treatment of sunitinib varied
more than tenfold among individual patients and had a
median value of 82 pg/ml (range 29–348, n = 19). These
median levels increased from 82 to 185 pg/ml on C1D14
(n = 19; P = 0.001), from median pre-treatment 79 to
198 pg/ml on C1D28 (n = 12; P = 0.028) and returned to
near pre-treatment levels on C2D1 (from 79 to 75 pg/ml;
n = 12, P = 0.875; Fig. 3b). In a subgroup of patients, we
assessed EPO levels and the median plasma EPO level on
C1D1 was 12 mIU/ml, which increased with 63% after
14 days (median, n = 20, Fig. 3c). In six patients, EPO was
measured during the complete cycle (Fig. 3d) showing
increases of 60 and 216% at days C1D14 and C1D28,
respectively, which remained above baseline level at C2D1.
Albumin concentrations determined in a larger group of
Fig. 2 Detection of hematopoietic progenitor cells (HPCs) and
circulating endothelial cells (CECs) using four-color flow cytometry.
The mononuclear(MNC)-fraction of a renal cell cancer (RCC) patient
on C1D1 and C1D14 (a) and human umbilical cord blood (b). In the
upper panel CD45, CD34 expression, size and granularity is shown
for HPCs and CECs. HPCs measured as CD45dim/CD34bright and
CECs measured as CD45neg/CD34bright (see box). Second and third
panel is showing CD133 expression for both HPCs and CECs when
compared with the isotype control
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RCC patients treated with sunitinib were unaltered at C1D28
(n = 67) in comparison with the initial values at C1D0,
n = 81 (median of 38 lmol/l range 17–50 lmol/l and
median of 41 lmol/l range 22–52 lmol/l, respectively).
Biomarkers and treatment outcome
Clinical benefit was observed in 15 out of 21 RCC patients.
Seventeen of all patients had clear cell RCC, of which 14
showed CB. PD was observed in 6 patients; 3 clear cell
RCC patients, 2 papillary carcinoma, and 1 chromophobe
carcinoma indicating that the patients with a clear cell
carcinoma had a good response to sunitinib. In the CB
group, the change in CECs after 14 days was increased in
14 out of 15 patients and in the PD group 4 out of 6 patients
showed an increase, while 2 had a decrease. An increased
number of CECs (n = 18) after 14 days of sunitinib
treatment, was associated with a longer PFS when com-
pared with patients (n = 3) with a decreased number of
CECs (log rank test; P = 0.034).
Discussion
We have investigated the changes in the frequency of cir-
culating cells with specific emphasis on a population of
small CD45neg/CD34bright CECs, previously shown to be
CD31pos/CD105pos/CD146pos/VEGFR2pos/CD133neg [19],
Fig. 3 Circulating endothelial
cells (CECs), total
hematopoietic progenitor cells
(HPCs), erythropoietin (EPO)
levels, and changes of VEGF
levels in comparison with
changes of blood cells during
treatment with sunitinib. a
Frequencies of CECs/ml and
viable HPCs/ml are shown
before (C1D1, n = 23), and on
C1D14 (n = 23), C1D28
(n = 14), and C2D1 (n = 14)
after start of sunitinib treatment.
b Percentage change in
circulating cells and plasma
VEGF levels on different time-
points during sunitinib
treatment are given. c and
d Plasma EPO levels are shown.
In (a), (c), and (d) individual
data and the median values are
shown, while in Fig. 3b pre-
treatment levels (C1D1) were
used as starting-point and
percentage of change on C1D14
(and other timepoints) was
calculated for each individual
patient. Wilcoxon Signed rank
test, * P \ 0.01, ** P \ 0.05,
ns not significant
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in advanced RCC patients during the first cycle of sunitinib
treatment. CECs increased in parallel to plasma VEGF and
EPO levels during the 4-week on and decreased during the
2-week off sunitinib period, while monocytes and HPCs
displayed an opposite pattern of change.
Blood cell-based biomarker analysis related to sunitinib
activity and clinical outcome has been studied only in
GIST patients with the main conclusion that a smaller
decrease in monocyte levels was seen in patients with
clinical benefit compared to those with PD [10]. We
observed a decrease in circulating monocyte number after
sunitinib treatment in RCC patients in agreement with the
GIST study; a correlation with response was not seen in our
population, possibly related to the limited number of
patients with PD.
The number of HPCs decreased already maximally at
C1D14 in our patient group, in parallel to the monocytes,
while the overall WBC count dropped more slowly, due to
a more delayed change in circulating neutrophils (Fig. 1).
The decrease in HPCs might be partly related to bone
marrow suppression associated with the Flt3-inhibitory
action of sunitinib, since Flt3-signaling is required for HPC
proliferation [26, 27].
Despite intense interest in developing biomarker tests
for response prediction [7, 28, 29], levels of CECs during
sunitinib treatment of RCC patients have not yet been
reported. Therefore, the most interesting and novel finding
of our study was the increase in CD45neg/CD34bright CECs
during sunitinib treatment. The CEC population in PB is a
rare cell population [20], which is increased two to three-
fold in cancer patients [19]. In the present patient group,
the median pre-treatment (C1D1) frequency of the CECs
was 69 cells/ml (n = 23), which is well-comparable to the
median of 81 cells/ml (range 32–132) in a mixed group of
cancer patients [19]. The number of CECs approximately
doubled in the RCC patient group by sunitinib treatment.
Since we found a similar twofold increase in CEC levels
(without decrease in HPC numbers) in a group of bev-
acizumab plus erlotinib, but not erlotinib-single agent
treated NSCLC patients (L. Vroling et al., unpublished)
[30], this increase is more likely related to inhibition of
VEGFR signaling by sunitinib, rather than to inhibition of
other targets or off-target effects of sunitinib. Being a most
likely specific target-related effect of sunitinib, this
increase in CECs remains an interesting cell population to
be further investigated.
An important question regards the precise nature and
function of the CEC population that is elevated after sun-
itinib treatment, in particular in the light of the current
controversies on the identification and role in tumor angi-
ogenesis of CECs or CEPs [11, 14, 25, 31]. A plausible
explanation for the increased number of CECs is that they
reflect endothelial cells, which became detached or shed
from sunitinib-targeted immature (tumor) blood vessels.
Although we have defined this population by the marker
combination of CD45neg and CD34bright, which are both
essential for discriminating these cells from the HPCs and
all other MNCs, in theory, it may still be heterogeneous
with regard to other EC markers. Importantly, we have
assessed that this population has the highest VEGFR2
positivity (median 65%) of all by us defined cell popula-
tions in the PB, further supporting their endothelial nature.
CECs are commonly characterized and defined by a het-
erogeneous, but rather large size and granularity, exceeding
that of most mononuclear cell populations, typically
[20 lm [22, 32, 33] and a high CD146 expression
allowing selective extraction with immunobeads [34]. The
median diameter of CD146? PBMCs has been estimated
6.8 lm versus that of CD146? CECs as 21.5 lm [22]. Our
CECs are in the FSC/SSC range of the HPCs, which are
\10 lm. This fits with the idea that these small CECs
originate from a rather immature vasculature and/or are
mobilized bone marrow or vascular wall resident EPCs. In
support of this explanation, several data suggest that sun-
itinib might selectively prune immature nascent tumor
neovessels not yet adequately stabilized by pericyte cov-
erage [35, 36], while relatively saving mature vessels
leading to vessel normalization [37].
A characteristic of endothelial cells in vitro is that they
rapidly become apoptotic after detachment from their
matrix [38]. However, in studies that measure CEC fre-
quencies in PB, cell viability was either not assessed or the
viability marker dye 7-AAD has been used to exclude dead
cells, as in most flow cytometric approaches. While our
CEC values are intact, CECs by the definition of exclusion
of 7-AAD, more sensitive markers, such as annexin-V
staining or the dye SYTO-16, can detect early stages of
apoptosis in cells that still exclude 7-AAD [39]. We are not
aware of studies reporting apoptotic CECs using annexin-V
labeling, probably because this technique is not readily
incorporated in most CEC protocols and also the use of
frozen-thawed samples as used by some [10] precludes the
reliable assessment of apoptotic cells [39]. Therefore, we
have assessed the percentage of apoptotic CECs with
annexin-V (with ammonium chloride) protocol in several
RCC patients, separately from the main study protocol and
found that the number of early apoptotic CECs was con-
siderable (range 50–80% of CECs).
It should be noted that the endothelial cell marker VE-
cadherin was virtually absent in most of our CEC sub-
populations, while others reported it to be present on
mature CECs circulating in PB [40]. The lack of overt
surface VE-cadherin expression may reflect the immature
nature of these small CECs, or might also be explained by
internalization during or after loss of endothelial junctions
and detachment of the cells [41, 42].
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An alternative possibility may be that our CD45neg/
CD34bright CECs have endothelial progenitor (CEP) char-
acteristics, such as those recently ascribed to CD45neg/
CD34bright/CD133neg cells [14, 15, 43, 44]. A disturbed
homing of VEGFR positive CEPs into the tumor vasculature
caused by sunitinib might also contribute to the increase in
CD45neg/CD34bright CEC population. It is important to note
that the presence of a fraction of early apoptotic cells in the
population of CECs does not exclude a priory the presence of
endothelial progenitor cells, capable of highly proliferative
outgrowth, since the CD34bright/CD45neg/CD133neg cell
population from cord blood, which is the source of late
EOCs, also contained up to 60% apoptotic cells (F. Tim-
mermans, personal communication). This lends support to
the idea that the EPCs or EOC precursors circulating in
human PB might be in majority rather resident cells from
peripheral sites than from the bone marrow [45] and might
exist in multiple states of differentiation [46].
In addition to the increase in CECs, the soluble growth
factor VEGF increased during sunitinib exposure and partly
normalized 2 weeks after cessation of drug intake. This
finding is in accordance with previous findings on VEGF
receptor inhibition studies in mice and man [10, 47, 48]. The
mechanism for the VEGF increase is not known, but
according to the study of Ebos et al. [49], may reflect a direct
or indirect physiological response to receptor inhibition by
sunitinib. Indeed, we found also a prominent increase in EPO
during the first cycle of sunitinib, consistent with the findings
of Ebos et al. [49] in sunitinib-treated mice. Functional
consequences of increased plasma EPO levels in sunitinib-
treated patients remain to be defined.
The rapid return of VEGF and CECs to the pre-treat-
ment levels during the 2-weeks rest period is remarkable.
Studies by McDonald et al. [50] have pointed to the rapid
repopulation of vascular casts after cessation of anti-
angiogenic treatment of tumor-bearing animals. The
occurrence of a similar rapid resumption of vessel repair in
the RCC patients might contribute to the rapid normali-
zation of VEGF during the drug-free period.
The primary goal of this study was to investigate the
presence and pattern of change of CD34bright/CD45neg
CECs, separated from CD34bright/CD45pos HPCs in a
cohort of sunitinib-treated RCC patients. The question,
whether the observed changes in CECs or other circulating
subsets of cells are just a pharmacodynamic marker of
sunitinib activity or might have a predictive value, needs to
be addressed in a larger cohort of patients [51, 52].
In conclusion, this study shows that CD34bright CECs
and CD34bright HPCs counts change in opposite directions
by sunitinib; monocytes and HPC decrease and CECs
increase. CD34bright/CD133neg CECs might be detached
ECs and reflect sunitinib anti-vascular effects or might
include CEPs, which are potential targets.
Acknowledgments We thank Corinne N. Tillier and Henk A. Mallo
for their help with patient care. Grant support: Supported by the
European Union (FP6) Integrated project ‘‘Angiotargeting’’ (contract
no. 504743). This study has been partly presented at the 99th AACR
Annual Meeting in San Diego, April 2008.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bev-
acizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:
10.1056/NEJMoa032691
2. Choueiri TK, Rini B, Garcia JA et al (2007) Prognostic factors
associated with long-term survival in previously untreated meta-
static renal cell carcinoma. Ann Oncol 18:249–255. doi:10.1093/
annonc/mdl371
3. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy
and safety of sunitinib in patients with advanced gastrointestinal
stromal tumour after failure of imatinib: a randomised controlled
trial. Lancet 368:1329–1338. doi:10.1016/S0140-6736(06)694
46-4
4. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus
interferon alfa in metastatic renal-cell carcinoma. N Engl J Med
356:115–124. doi:10.1056/NEJMoa065044
5. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib
in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:
125–134. doi:10.1056/NEJMoa060655
6. Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of suni-
tinib and sorafenib in metastatic papillary and chromophobe renal
cell carcinoma. J Clin Oncol 26:127–131. doi:10.1200/JCO.2007.
13.3223
7. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from
phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin
Pract Oncol 3:24–40. doi:10.1038/ncponc0403
8. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al (2005) Soluble
markers for the assessment of biological activity with PTK787/ZK
222584 (PTK/ZK), a vascular endothelial growth factor receptor
(VEGFR) tyrosine kinase inhibitor in patients with advanced
colorectal cancer from two phase I trials. Ann Oncol 16: 558–565.
doi:10.1093/annonc/mdi118
9. Bocci G, Man S, Green SK et al (2004) Increased plasma vascular
endothelial growth factor (VEGF) as a surrogate marker for
optimal therapeutic dosing of VEGF receptor-2 monoclonal
antibodies. Cancer Res 64:6616–6625. doi:10.1158/0008-5472.
CAN-04-0401
10. Norden-Zfoni A, Desai J, Manola J et al (2007) Blood-based
biomarkers of SU11248 activity and clinical outcome in patients
with metastatic imatinib-resistant gastrointestinal stromal tumor.
Clin Cancer Res 13:2643–2650. doi:10.1158/1078-0432.CCR-
06-0919
11. Le Tourneau C, Vidal L, Siu LL (2008) Progress and challenges
in the identification of biomarkers for EGFR and VEGFR tar-
geting anticancer agents. Drug Resist Updat 11:99–109. doi:
10.1016/j.drup.2008.04.001
12. Asahara T, Masuda H, Takahashi T et al (1999) Bone marrow
origin of endothelial progenitor cells responsible for postnatal
vasculogenesis in physiological and pathological neovasculari-
zation. Circ Res 85:221–228
Angiogenesis (2009) 12:69–79 77
123
13. Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of
bone-marrow-derived endothelial and hematopoietic precursor
cells blocks tumor angiogenesis and growth. Nat Med 7:1194–
1201. doi:10.1038/nm1101-1194
14. Hirschi KK, Ingram DA, Yoder MC (2008) Assessing identity,
phenotype, and fate of endothelial progenitor cells. Arterioscler
Thromb Vasc Biol 28:1584–1595. doi:10.1161/ATVBAHA.107.
155960
15. Timmermans F, Van Hauwermeiren F, De Smedt M et al (2007)
Endothelial outgrowth cells are not derived from CD133? cells
or CD45? hematopoietic precursors. Arterioscler Thromb Vasc
Biol 27:1572–1579. doi:10.1161/ATVBAHA.107.144972
16. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171,
a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor
vasculature and alleviates edema in glioblastoma patients. Cancer
Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021
17. Duda DG, Cohen KS, di Tomaso E et al (2006) Differential
CD146 expression on circulating versus tissue endothelial cells in
rectal cancer patients: implications for circulating endothelial and
progenitor cells as biomarkers for antiangiogenic therapy. J Clin
Oncol 24:1449–1453. doi:10.1200/JCO.2005.04.2861
18. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence
that the VEGF-specific antibody bevacizumab has antivascular
effects in human rectal cancer. Nat Med 10:145–147. doi:10.1038/
nm988
19. Vroling L, Yuana Y, Schuurhuis GJ et al (2007) VEGFR2
expressing circulating (progenitor) cell populations in volunteers
and cancer patients. Thromb Haemost 98:440–450
20. Delorme B, Basire A, Gentile C et al (2005) Presence of
endothelial progenitor cells, distinct from mature endothelial
cells, within human CD146? blood cells. Thromb Haemost 94:
1270–1279
21. Blann AD, Woywodt A, Bertolini F et al (2005) Circulating
endothelial cells. Biomarker of vascular disease. Thromb Hae-
most 93:228–235
22. Clarke LA, Shah V, Arrigoni F et al (2008) Quantitative detection
of circulating endothelial cells in vasculitis: comparison of flow
cytometry and immunomagnetic bead extraction. J Thromb
Haemost 6:1025–1032. doi:10.1111/j.1538-7836.2008.02953.x
23. Wu H, Chen H, Hu PC (2007) Circulating endothelial cells and
endothelial progenitors as surrogate biomarkers in vascular dys-
function. Clin Lab (Zaragoza) 53:285–295
24. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New
guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/
jnci/92.3.205
25. Strijbos MH, Kraan J, den Bakker MA et al (2007) Cells meeting
our immunophenotypic criteria of endothelial cells are large
platelets. Cytometry B Clin Cytom 72:86–93. doi:10.1002/cyto.b.
20156
26. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular
basis for sunitinib efficacy and future clinical development. Nat
Rev Drug Discov 6:734–745. doi:10.1038/nrd2380
27. Gabbianelli M, Pelosi E, Montesoro E et al (1995) Multi-level
effects of flt3 ligand on human hematopoiesis: expansion of
putative stem cells and proliferation of granulomonocytic pro-
genitors/monocytic precursors. Blood 86:1661–1670
28. Broxterman HJ, Georgopapadakou NH (2007) Anticancer thera-
peutics: a surge of new developments increasingly target tumor
and stroma. Drug Resist Updat 10:182–193. doi:10.1016/j.drup.
2007.07.001
29. Shaked Y, Ciarrocchi A, Franco M et al (2006) Therapy-induced
acute recruitment of circulating endothelial progenitor cells to
tumors. Science 313:1785–1787. doi:10.1126/science.1127592
30. Vroling L, van der Veldt AM, de Haas RR et al (2008)
CD34bright/CD133neg candidate circulating endothelial pro-
genitor cells (ccEPCs) are a potential biomarker during treatment
with sunitinib or bevacizumab. AACR Meeting Abstracts. 2008:
4956
31. Purhonen S, Palm J, Rossi D et al (2008) Bone marrow-derived
circulating endothelial precursors do not contribute to vascular
endothelium and are not needed for tumor growth. Proc Natl
Acad Sci USA 105:6620–6625. doi:10.1073/pnas.0710516105
32. Goon PK, Boos CJ, Lip GY (2005) Circulating endothelial cells:
markers of vascular dysfunction. Clin Lab (Zaragoza) 51:531–538
33. Woywodt A, Blann AD, Kirsch T et al (2006) Isolation and
enumeration of circulating endothelial cells by immunomagnetic
isolation: proposal of a definition and a consensus protocol. J
Thromb Haemost 4:671–677. doi:10.1111/j.1538-7836.2006.
01794.x
34. Widemann A, Sabatier F, Arnaud L et al (2008) CD146-based
immunomagnetic enrichment followed by multiparameter flow
cytometry: a new approach to counting circulating endothelial
cells. J Thromb Haemost 6:869–876. doi:10.1111/j.1538-7836.
2008.02931.x
35. Palmowski M, Huppert J, Hauff P et al (2008) Vessel fractions in
tumor xenografts depicted by flow- or contrast-sensitive three-
dimensional high-frequency Doppler ultrasound respond differ-
ently to antiangiogenic treatment. Cancer Res 68:7042–7049. doi:
10.1158/0008-5472.CAN-08-0285
36. Zhou Q, Guo P, Gallo JM (2008) Impact of angiogenesis inhibition
by sunitinib on tumor distribution of temozolomide. Clin Cancer
Res 14:1540–1549. doi:10.1158/1078-0432.CCR-07-4544
37. Jain RK (2005) Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy. Science 307:58–62. doi:10.1126/
science.1104819
38. Re F, Zanetti A, Sironi M et al (1994) Inhibition of anchorage-
dependent cell spreading triggers apoptosis in cultured human endo-
thelial cells. J Cell Biol 127:537–546. doi:10.1083/jcb.127.2.537
39. Schuurhuis GJ, Muijen MM, Oberink JW et al (2001) Large
populations of non-clonogenic early apoptotic CD34-positive
cells are present in frozen-thawed peripheral blood stem cell
transplants. Bone Marrow Transplant 27:487–498. doi:10.1038/
sj.bmt.1702809
40. Jacques N, Vimond N, Conforti R et al (2008) Quantification of
circulating mature endothelial cells using a whole blood four-
color flow cytometric assay. J Immunol Methods 337:132–143.
doi:10.1016/j.jim.2008.07.006
41. Gavard J, Gutkind JS (2006) VEGF controls endothelial-cell
permeability by promoting the beta-arrestin-dependent endocy-
tosis of VE-cadherin. Nat Cell Biol 8:1223–1234. doi:10.1038/
ncb1486
42. Xiao K, Garner J, Buckley KM et al (2005) p120-Catenin regu-
lates clathrin-dependent endocytosis of VE-cadherin. Mol Biol
Cell 16:5141–5151. doi:10.1091/mbc.E05-05-0440
43. Case J, Mead LE, Bessler WK et al (2007) Human CD34(?)
AC133(?)VEGFR-2(?) cells are not endothelial progenitor cells
but distinct, primitive hematopoietic progenitors. Exp Hematol
35:1109–1118. doi:10.1016/j.exphem.2007.04.002
44. Timmermans F, Plum J, Yoder MC et al (2009) Endothelial
progenitor cells: identity defined? J Cell Mol Med 13:87–102.
doi:10.1111/j.1582-4934.2008.00598.x
45. Aicher A, Rentsch M, Sasaki K et al (2007) Nonbone marrow-
derived circulating progenitor cells contribute to postnatal neo-
vascularization following tissue ischemia. Circ Res 100:581–589.
doi:10.1161/01.RES.0000259562.63718.35
46. Barber CL, Iruela-Arispe ML (2006) The ever-elusive endothelial
progenitor cell: identities, functions and clinical implications.
Pediatr Res 59:26R–32R. doi:10.1203/01.pdr.0000203553.464
71.18
78 Angiogenesis (2009) 12:69–79
123
47. DePrimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein
biomarkers of pharmacodynamic activity of sunitinib in patients
with metastatic renal cell carcinoma: modulation of VEGF and
VEGF-related proteins. J Transl Med 5:32. doi:10.1186/1479-
5876-5-32
48. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of
SU11248, a multitargeted inhibitor of vascular endothelial
growth factor receptor and platelet-derived growth factor recep-
tor, in patients with metastatic renal cell carcinoma. J Clin Oncol
24:16–24. doi:10.1200/JCO.2005.02.2574
49. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007)
Multiple circulating proangiogenic factors induced by sunitinib
malate are tumor-independent and correlate with antitumor effi-
cacy. Proc Natl Acad Sci USA 104:17069–17074. doi:10.1073/
pnas.0708148104
50. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular
regrowth in tumors after reversal of VEGF inhibition. J Clin
Invest 116:2610–2621. doi:10.1172/JCI24612
51. Shojaei F, Ferrara N (2008) Role of the microenvironment in
tumor growth and in refractoriness/resistance to anti-angiogenic
therapies. Drug Resist Updat 11:219–230. doi:10.1016/j.drup.
2008.09.001
52. van Cruijsen H, van der Veldt AM, Vroling L et al (2008) Sun-
itinib-induced myeloid lineage redistribution in renal cell cancer
patients: CD1c? dendritic cell frequency predicts progression-
free survival. Clin Cancer Res 14:5884–5892. doi:10.1158/1078-
0432.CCR-08-0656
53. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002)
Interferon-alfa as a comparative treatment for clinical trials of
new therapies against advanced renal cell carcinoma. J Clin
Oncol 20:289–296. doi:10.1200/JCO.20.1.289
Angiogenesis (2009) 12:69–79 79
123
